Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer

NCT05450029 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: Sintilimab

Sponsor

Yanhong Deng

Collaborators

[object Object]